Jubilant HollisterStier nets US government contract to increase activity at its growing facility

31 May 2022
endpts.com
VaccineEmergency Use Authorization
A pharmaceutical contract manufacturer that has been growing its presence in the US has secured itself a sizable contract from the US government. Jubilant HollisterStier, a subsidiary of Singapore-based Jubilant Pharma Limited, has entered into a cooperative agreement for $149.6 million with the Army Contracting Command. The deal is also in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) on behalf of BARDA. The effort, which was funded under the American Rescue Plan, will enable Jubilant HollisterStier to double its injectable filling production capacity at its Spokane, WA manufacturing facility for a total cost $193 million. The project is slated completion in 2025, according to the company. The company has a history of supporting both HHS and the DOD with biodefense and medical countermeasure programs, including production for national preparedness efforts. “Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers,” Jubilant Pharma CEO Pramod Yadav said in a statement. In 2021 , Jubilant sought to expand its sterile injectable manufacturing capacity at its Spokane site to keep up with the demand surrounding the Covid-19 vaccineCovid-19 vaccine push. The initial $92 million investment is planned to increase manufacturing capacity by 50% with the inclusion of 2,300-square-foot lyophilizers and 50,000 square feet of building space. The upgrades will allow for 400 vials a minute to be filled. Earlier last year, the company also struck a deal with Eli Lilly for the manufacturing of bamlanivimab at the Spokane plant, however, bamlanivimab’s emergency use authorization was revoked by the FDA for the treatment of Covid-19. In 2021, the company announced that it had signed on with Novavax to provide fill-finish services to its vaccine candidate as well.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.